Alexander disease is a rare, fatal brain disorder caused by a single gene mutation that damages the brain’s white matter. It affects roughly one in every 2.7 million people worldwide, making it one of the rarest neurological conditions known. The disease belongs to a group of disorders called leukodystrophies, which destroy myelin, the protective insulation around nerve fibers that allows signals to travel quickly through the brain and spinal cord.
What Causes Alexander Disease
Alexander disease is caused by a mutation in the gene that produces a protein called GFAP, the main structural protein inside astrocytes. Astrocytes are star-shaped brain cells that support neurons, regulate chemical balance, and help maintain the blood-brain barrier. When the GFAP gene carries a mutation, the protein it produces doesn’t fold correctly. Instead of forming a healthy internal scaffold, the defective protein clumps together inside astrocytes, forming dense deposits called Rosenthal fibers.
These protein clumps set off a destructive chain reaction. The astrocyte’s internal waste-disposal system becomes overwhelmed, its ability to regulate brain chemicals breaks down, and the cell enters a state of chronic stress. In response, the body produces even more GFAP, which only accelerates the buildup. Over time, this cycle damages the surrounding white matter and progressively impairs brain function.
The mutation is dominant, meaning a single copy of the altered gene is enough to cause disease. In the vast majority of cases, the mutation is not inherited from a parent. Instead, it arises spontaneously (de novo) in the affected person. This means most families have no prior history of the condition before a child is diagnosed.
Type I vs. Type II
Clinicians divide Alexander disease into two main types based on when symptoms appear and which parts of the brain are most affected.
Type I is the more severe form. It typically begins in infancy or early childhood and has a median survival of about 14 years from onset. The hallmarks include seizures, an abnormally large head (macrocephaly, often with a prominent forehead), developmental delays, progressive loss of motor skills, and failure to thrive. Brain imaging in Type I usually shows extensive white matter damage concentrated in the frontal lobes.
Type II tends to appear later, from later childhood through adulthood, and progresses more slowly. Median survival is around 25 years. Rather than seizures and a large head, Type II is defined by problems with the brainstem and spinal cord: difficulty speaking, difficulty swallowing, unsteady gait, abnormal eye movements, and dysfunction of the autonomic nervous system (the system that controls things like digestion and blood pressure). Cognitive abilities are often preserved much longer than in Type I.
Symptoms in Infants and Young Children
The infantile form of Alexander disease usually becomes apparent within the first two years of life. Parents often notice that a baby’s head is growing faster than expected, sometimes with a prominent forehead. Developmental milestones like sitting, crawling, and walking are delayed or lost after initially being reached. Seizures are common and can be difficult to control. As the disease progresses, children develop increasing muscle stiffness (spasticity) and lose the ability to feed, move, and communicate independently. The course is typically rapid and severe.
Symptoms in Older Children and Adults
When Alexander disease begins later in life, the symptoms look quite different. A case report of a 67-year-old woman illustrates the pattern well: over two years she developed progressively slurred speech, difficulty swallowing, worsening balance, and an unsteady wide-based walk. She also experienced dizziness, chronic constipation, and trouble moving her eyes smoothly. Neurological examination revealed increased reflexes, stiffness in her legs, and rhythmic involuntary movements of the soft palate.
This bulbar-predominant pattern, centered on the brainstem structures that control swallowing, speech, and eye movement, is the signature of adult-onset Alexander disease. Progression is slow, often unfolding over years or even decades, which can make diagnosis difficult since these symptoms overlap with many other neurological conditions.
How Alexander Disease Is Diagnosed
MRI of the brain is the primary tool for raising suspicion of Alexander disease. Radiologists look for a specific combination of findings. In Type I, the classic pattern includes widespread white matter abnormalities that are worst in the frontal lobes, a distinctive rim of abnormal signal around the fluid-filled ventricles, changes in deep brain structures like the basal ganglia and thalamus, abnormalities in the brainstem, and areas of contrast enhancement in multiple brain structures. Meeting four of these five criteria on MRI is considered sufficient for a radiological diagnosis.
Type II shows a different imaging pattern, with abnormalities concentrated in the brainstem and upper spinal cord rather than the frontal white matter. This can make the MRI less immediately recognizable as Alexander disease.
A definitive diagnosis requires genetic testing to confirm a mutation in the GFAP gene. Because the mutations are almost always de novo, testing of the parents typically comes back negative.
Treatment and Outlook
There is currently no cure for Alexander disease, and treatment focuses on managing symptoms. Seizures are treated with anti-seizure medications. Physical therapy helps maintain mobility and manage spasticity. Speech and swallowing therapy can support nutrition and communication as bulbar symptoms progress. Some patients eventually need feeding tubes or other supportive interventions.
The most promising experimental approach targets the root cause. A drug called zilganersen (also known as ION373) is being tested in a Phase 1-3 clinical trial involving approximately 73 patients. It works by reducing the production of GFAP protein in the brain, aiming to slow or stop the toxic buildup that drives the disease. The drug is delivered by injection into the spinal fluid every 12 weeks. The trial includes a 60-week blinded treatment period followed by open-label extension periods lasting several years. As of recent updates, the trial is active but no longer recruiting new participants.
Life expectancy varies considerably by type and even within types. Type I carries a median survival of 14 years, though individual trajectories differ. Type II patients have a median survival of 25 years, and some adults with slowly progressive forms live significantly longer. The wide range in outcomes reflects the diversity of mutations, the age at which symptoms begin, and how quickly the disease progresses in each person.